Francisco J. Esteva: KEYNOTE-522 Trial Shows Pembrolizumab Boosts Survival in Triple-Negative Breast Cancer
Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital, posted the following on LinkedIn:
“The KEYNOTE-522 trial shows that adding pembrolizumab to the standard neoadjuvant chemotherapy significantly boosts outcomes for early-stage triple-negative breast cancer patients. The study previously found higher pathological complete response rates, along with better event-free survival.
A recent update showed a significant improvement in overall survival rate, compared to just chemotherapy, cutting the risk of death by more than 34%.
This is great news for patients with high-risk early-stage triple-negative breast cancer, confirming immunotherapy is a major advance in breast cancer therapy.”
Source: Francisco J. Esteva/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023